With the players featured in our rundown of the top 10 generics and biosimilars companies this year remaining a fairly stable set (see sidebar), our middle table covering positions 11-30 in our ranking offers a little more in the way of surprises, in the second part of this year’s Generics Bulletin Top 50.
The Generics Bulletin Top 50, Part Two: Major Shifts Bring Ups And Downs For Mid-Ranked Players
Mid-Table Movements See Some Firms Rising Up The Rankings While Others Slide
In the second part of Generics Bulletin’s Top 50, we see some companies rising up the rankings of generics and biosimilars players worldwide, passing others that are moving in the opposite direction.
